As of 2025-10-20, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 16.1x | 11.9x |
| Forward P/E multiples | 13.1x - 16.0x | 15.6x |
| Fair Price | (148.65) - (180.85) | (155.24) |
| Upside | -186.2% - -204.9% | -190.1% |
| Date | EV/EBITDA |